Παρακαλώ χρησιμοποιήστε αυτό το αναγνωριστικό για να παραπέμψετε ή να δημιουργήσετε σύνδεσμο προς αυτό το τεκμήριο:
https://hdl.handle.net/20.500.14279/22712
Πεδίο DC | Τιμή | Γλώσσα |
---|---|---|
dc.contributor.author | Grant, Rebecca | - |
dc.contributor.author | Dub, Timothée | - |
dc.contributor.author | Andrianou, Xanthi | - |
dc.contributor.author | Nohynek, Hanna | - |
dc.contributor.author | Wilder-Smith, Annelies | - |
dc.contributor.author | Pezzotti, Patrizio | - |
dc.contributor.author | Fontanet, Arnaud | - |
dc.date.accessioned | 2021-06-17T06:59:34Z | - |
dc.date.available | 2021-06-17T06:59:34Z | - |
dc.date.issued | 2021-04-01 | - |
dc.identifier.citation | BMJ Open, 2021, vol. 11, no. 4, articl. no. e045425 | en_US |
dc.identifier.issn | 20446055 | - |
dc.identifier.uri | https://hdl.handle.net/20.500.14279/22712 | - |
dc.description.abstract | Objectives We aimed to review SARS-CoV-2 seroprevalence studies conducted in Europe to understand how they may be used to inform ongoing control strategies for COVID-19. Design Scoping review of peer-reviewed publications and manuscripts on preprint servers from January 2020 to 15 September 2020. Primary measure Seroprevalence estimate (and lower and upper CIs). For studies conducted across a country or territory, we used the seroprevalence estimate and the upper and lower CIs and compared them to the total number of reported infections to calculate the ratio of reported to expected infections. Results We identified 23 population-based seroprevalence studies conducted in Europe. Among 12 general population studies, seroprevalence ranged from 0.42% among residual clinical samples in Greece to 13.6% in an area of high transmission in Gangelt, Germany. Of the eight studies in blood donors, seroprevalence ranged from 0.91% in North-Western Germany to 23.3% in a high-transmission area in Lombardy region, Italy. In three studies which recruited individuals through employment, seroprevalence ranged from 0.5% among factory workers in Frankfurt, Germany, to 10.2% among university employees in Milan, Italy. In comparison to nationally reported cases, the extent of infection, as derived from these seroprevalence estimates, is manyfold higher and largely heterogeneous. Conclusion Exposure to the virus in Europe has not reached a level of infection that would prevent further circulation of the virus. Effective vaccine candidates are urgently required to deliver the level of immunity in the population. | en_US |
dc.format | en_US | |
dc.language.iso | en | en_US |
dc.relation.ispartof | BMJ open | en_US |
dc.rights | © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. | en_US |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Epidemiology | en_US |
dc.subject | Public health | en_US |
dc.title | SARS-CoV-2 population-based seroprevalence studies in Europe: a scoping review | en_US |
dc.type | Article | en_US |
dc.collaboration | Institut Pasteur | en_US |
dc.collaboration | Finnish Institute for Health and Welfare | en_US |
dc.collaboration | Italian National Health Institute | en_US |
dc.collaboration | Cyprus University of Technology | en_US |
dc.collaboration | London School of Hygiene and Tropical Medicine | en_US |
dc.collaboration | University of Heidelberg | en_US |
dc.collaboration | Conservatoire National des Arts et Métiers | en_US |
dc.subject.category | Health Sciences | en_US |
dc.journals | Open Access | en_US |
dc.country | France | en_US |
dc.country | Finland | en_US |
dc.country | Italy | en_US |
dc.country | Cyprus | en_US |
dc.country | United Kingdom | en_US |
dc.country | Germany | en_US |
dc.subject.field | Medical and Health Sciences | en_US |
dc.publication | Peer Reviewed | en_US |
dc.identifier.doi | 10.1136/bmjopen-2020-045425 | en_US |
dc.identifier.pmid | 33795310 | - |
dc.identifier.scopus | 2-s2.0-85103772543 | - |
dc.identifier.url | https://api.elsevier.com/content/abstract/scopus_id/85103772543 | - |
dc.relation.issue | 4 | en_US |
dc.relation.volume | 11 | en_US |
cut.common.academicyear | 2020-2021 | en_US |
item.languageiso639-1 | en | - |
item.cerifentitytype | Publications | - |
item.fulltext | With Fulltext | - |
item.grantfulltext | open | - |
item.openairetype | article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
crisitem.author.dept | Cyprus International Institute for Environmental and Public Health | - |
crisitem.author.faculty | Faculty of Health Sciences | - |
crisitem.author.orcid | 0000-0002-2906-5743 | - |
crisitem.author.parentorg | Faculty of Health Sciences | - |
crisitem.journal.journalissn | 2044-6055 | - |
crisitem.journal.publisher | BMJ | - |
Εμφανίζεται στις συλλογές: | Άρθρα/Articles |
Αρχεία σε αυτό το τεκμήριο:
Αρχείο | Περιγραφή | Μέγεθος | Μορφότυπος | |
---|---|---|---|---|
e045425.full.pdf | Fulltext | 2.32 MB | Adobe PDF | Δείτε/ Ανοίξτε |
e045425.full.pdf | Supplementary Material | 2.36 MB | Adobe PDF | Δείτε/ Ανοίξτε |
CORE Recommender
SCOPUSTM
Citations
32
checked on 2 Φεβ 2024
WEB OF SCIENCETM
Citations
31
Last Week
0
0
Last month
0
0
checked on 29 Οκτ 2023
Page view(s)
277
Last Week
0
0
Last month
5
5
checked on 6 Οκτ 2024
Download(s)
234
checked on 6 Οκτ 2024
Google ScholarTM
Check
Altmetric
Αυτό το τεκμήριο προστατεύεται από άδεια Άδεια Creative Commons